In response to a wide variety of stimuli, the heart has the ability to undergo hypertrophic growth. Hypertrophy can be a physiologic adaptive process during development or in response to exercise. It is initially adaptive after a pathological stimulus such as pressure overload but can become maladaptive and is, in fact, a leading predictor of congestive heart failure. The regulatory feedback systems leading to hypertrophy include a variety of intracellular factors and signaling cascades. Because the multiple factors and signaling pathways activated under these conditions are common to both stimuli, it is critical to understand which common and distinct pathways lead to pathologic versus physiological hypertrophy. We will use several transgenic models to help delineate the signaling processes involved in the progression of pathologic and physiologic hypertrophy. The cardiac phenotype of a transgenic line lacking an intracellular messenger (MEKKI) of a hypertrophic signaling cascade will be characterized for its response to pathologic and physiologic hypertrophic stimuli. In addition, this mouse will be crossed to three, well-characterized transgenic models for hypertrophic cardiomyopathy (HCM), which harbor specific mutations in cardiac sarcomeric proteins. One of these transgenic models has a mutation in the actin-binding domain of the murine a-myosin heavy chain (a-MHC) and is characterized by a gender specific increased ventricular mass. Additional models contain a missense mutation of cardiac troponin T (cTnT) or a truncated cTnT. Interestingly, cTnT mutations result in significantly decreased ventricular mass. These crossed animals will be analyzed to determine the integration and contribution of the MEKK1 intracellular pathway to the varied Phenotypes of HCM.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
5F32HL070509-03
Application #
6721398
Study Section
Special Emphasis Panel (ZRG1-F10 (20))
Program Officer
Commarato, Michael
Project Start
2002-04-02
Project End
2005-04-01
Budget Start
2004-04-02
Budget End
2005-04-01
Support Year
3
Fiscal Year
2004
Total Cost
$48,928
Indirect Cost
Name
University of Colorado at Boulder
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
007431505
City
Boulder
State
CO
Country
United States
Zip Code
80309
Haines, Christopher D; Harvey, Pamela A; Luczak, Elizabeth D et al. (2012) Estrogenic compounds are not always cardioprotective and can be lethal in males with genetic heart disease. Endocrinology 153:4470-9
Konhilas, John P; Boucek, Dana M; Horn, Todd R et al. (2010) The role of MEKK1 in hypertrophic cardiomyopathy. Int Heart J 51:277-84
Rosedale, Ron; Westman, Eric C; Konhilas, John P (2009) Clinical Experience of a Diet Designed to Reduce Aging. J Appl Res 9:159-165
Konhilas, John P; Leinwand, Leslie A (2007) The effects of biological sex and diet on the development of heart failure. Circulation 116:2747-59
Konhilas, John P; Watson, Peter A; Maass, Alexander et al. (2006) Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res 98:540-8
Konhilas, John P; Leinwand, Leslie A (2006) Partnering up for cardiac hypertrophy. Circ Res 98:985-7
Stauffer, Brian L; Konhilas, John P; Luczak, Elizabeth D et al. (2006) Soy diet worsens heart disease in mice. J Clin Invest 116:209-16
Konhilas, John P; Widegren, Ulrika; Allen, David L et al. (2005) Loaded wheel running and muscle adaptation in the mouse. Am J Physiol Heart Circ Physiol 289:H455-65
Konhilas, John P; Maass, Alexander H; Luckey, Stephen W et al. (2004) Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ Physiol 287:H2768-76
Maass, A; Konhilas, J P; Stauffer, B L et al. (2002) From sarcomeric mutations to heart disease: understanding familial hypertrophic cardiomyopathy. Cold Spring Harb Symp Quant Biol 67:409-15